NCT06442423View on ClinicalTrials.gov

Open-Label Psilocybin Study in Transdiagnostic Population

PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 17, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
TransdiagnosticDepression - Major Depressive DisorderAnxietyPTSD SymptomsPTSDSubstance UseSubstance Use Disorder (SUD)OCD
Interventions
DRUG

Psilocybin

Psilocybin will be administered in an opaque, size 2 gelatin capsule with approximately 180 ml of water to be orally ingested at Visit 5. The dose of psilocybin will be 25 mg.This is an open-label clinical trial with a single treatment arm. This is an open-label clinical trial with no blinding.

Trial Locations (1)

06519

RECRUITING

Connecticut Mental Health Center - Yale School of Medicine, New Haven

All Listed Sponsors
collaborator

Usona Institute

OTHER

lead

Yale University

OTHER